Amgen Overview

  • Year Founded
  • 1980

Year Founded

  • Status
  • Public

  • Employees
  • 28,000

Employees

  • Stock Symbol
  • AMGN

Stock Symbol

  • Investments
  • 70

  • Share Price
  • $273.68
  • (As of Monday Closing)

Amgen General Information

Description

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Contact Information

Website
www.amgen.com
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • One Amgen Center Drive
  • Thousand Oaks, CA 91320-1799
  • United States
+1 (805)
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
NAS
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • One Amgen Center Drive
  • Thousand Oaks, CA 91320-1799
  • United States
+1 (805)

Amgen Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Amgen Stock Performance

As of 21-Apr-2025, Amgen’s stock price is $273.68. Its current market cap is $147B with 538M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$273.68 $277.29 $253.30 - $346.85 $147B 538M 3.25M $7.62

Amgen Financials Summary

As of 31-Dec-2024, Amgen has a trailing 12-month revenue of $33.4B.

In Thousands,
USD 		TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 191,489,529 191,489,529 179,868,975 167,365,243
Revenue 33,424,000 33,424,000 28,190,000 26,323,000
EBITDA 13,258,000 13,258,000 14,615,000 12,013,000
Net Income 4,090,000 4,090,000 6,717,000 6,552,000
Total Assets 91,839,000 91,839,000 97,154,000 65,121,000
Total Debt 60,099,000 60,099,000 64,613,000 38,945,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Amgen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Amgen‘s full profile, request access.

Request a free trial

Amgen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and A
Other Pharmaceuticals and Biotechnology
Thousand Oaks, CA
28,000 As of 2024

Indianapolis, IN
 

Foster City, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Amgen Competitors (25)

One of Amgen’s 25 competitors is Eli Lilly and Company, a Corporation company based in Indianapolis, IN.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Eli Lilly and Company Corporation Indianapolis, IN
Gilead Sciences Formerly VC-backed Foster City, CA
Bristol-Myers Squibb Corporation Princeton, NJ
Regeneron Pharmaceuticals Formerly VC-backed Tarrytown, NY
AbbVie Corporation North Chicago, IL
You’re viewing 5 of 25 competitors. Get the full list »

Amgen Patents

  • 16,642

    Total Documents Applications and Grants

  • Total Patents Families

  • 7,700

    Granted

  • 2,614

    Pending

  • Expiring in next 12 mo

Amgen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-D1071163-S1 Handheld drug delivery device Active 14-Nov-2023
US-D1051367-S1 Handheld drug delivery device Active 25-Sep-2023
US-D1050422-S1 Handheld drug delivery device Active 25-Sep-2023
US-D1049369-S1 Handheld drug delivery device Active 25-Sep-2023
US-20250105702-A1 Electric motor system Pending 25-Sep-2023 H02K9/06
To view Amgen’s complete patent history, request access »

Amgen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amgen Investments & Acquisitions (70)

Amgen’s most recent deal was a Later Stage VC with BioAge Labs for . The deal was made on 01-Feb-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
BioAge Labs 01-Feb-2024 Later Stage VC Drug Discovery
Quantinuum 16-Jan-2024 Early Stage VC Application Specific Semiconductors
Horizon Therapeutics 06-Oct-2023 Merger/Acquisition Pharmaceuticals
Generate:Biomedicines 06-Sep-2023 Later Stage VC Biotechnology
Chemocentryx 20-Oct-2022 Merger/Acquisition Pharmaceuticals
You’re viewing 5 of 70 investments and acquisitions. Get the full list »

Ready to get started?

Request a free trial

Amgen ESG

Risk Overview

Risk Rating

Updated March, 26, 2025

22.53 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,109

Rank

Percentile

Pharmaceuticals

Industry

of 861

Rank

Percentile

Biotechnology

Subindustry

of 371

Rank

Percentile

To view Amgen’s complete esg history, request access »

Amgen Exits (22)

Amgen’s most recent exit was on 01-Feb-2024 from BioAge Labs. The exit was categorized as with 15 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
BioAge Labs 01-Feb-2024 Completed
  • 15 buyers
Jasper Therapeutics 24-Sep-2021 Completed
  • 13 buyers
SomaLogic Operating Company 25-Nov-2020 Completed
  • 22 buyers
Carmot Therapeutics 30-Sep-2020 Completed
  • 3 buyers
Provention Bio 24-Sep-2019 PIPE Completed
You’re viewing 5 of 22 exits. Get the full list »

Amgen Affiliates

Subsidiaries (6)

Name Industry Location Year Founded
Amgen Astellas BioPharma Tokyo, Japan 2013
Amgen Ventures Thousand Oaks, CA 2004
Amgen Safety Net Foundation Newbury Park, CA 2001
Decode Genetics Reykjavik, Iceland 1996
Amgen Master Benefits Plan Thousand Oaks, CA 1991
You’re viewing 5 of 6 affiliates. Get the full list.  »

Amgen FAQs

  • When was Amgen founded?

    Amgen was founded in 1980.

  • Where is Amgen headquartered?

    Amgen is headquartered in Thousand Oaks, CA.

  • What is the size of Amgen?

    Amgen has 28,000 total employees.

  • What industry is Amgen in?

    Amgen’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Amgen a private or public company?

    Amgen is a Public company.

  • What is Amgen’s stock symbol?

    The ticker symbol for Amgen is AMGN.

  • What is the current stock price of Amgen?

    As of 21-Apr-2025 the stock price of Amgen is $273.68.

  • What is the current market cap of Amgen?

    The current market capitalization of Amgen is $147B.

  • What is Amgen’s current revenue?

    The trailing twelve month revenue for Amgen is $33.4B.

  • Who are Amgen’s competitors?

    Eli Lilly and Company, Gilead Sciences, Bristol-Myers Squibb, Regeneron Pharmaceuticals, and AbbVie are some of the 25 competitors of Amgen.

  • What is Amgen’s annual earnings per share (EPS)?

    Amgen’s EPS for 12 months was $7.62.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »